ZIMMER BIOMET HOLDINGS Business Summary

Zimmer Biomet Holdings, Inc. (ZBH) is a global leader in musculoskeletal healthcare, generating revenue primarily through the design, manufacture, and marketing of orthopedic reconstructive implants, robotic surgical assistants, and integrated digital health suites. The company’s business is organized into three primary segments: Knees, Hips, and S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial, and Thoracic). ZBH utilizes a high-density sales model centered on its ROSA Robotics platform, which acts as a strategic catalyst for the recurring pull-through of proprietary consumables and high-margin implant systems. Its primary competitors include Stryker Corporation, DePuy Synthes (a subsidiary of Johnson & Johnson), and Smith & Nephew. Zimmer Biomet maintains a dominant position in the global large-joint reconstruction market, differentiating itself through the ZBEdge digital ecosystem, which leverages data analytics and AI to optimize perioperative surgical workflows and patient outcomes. Founded in 1927 by Justin O. Zimmer, the company is currently led by President and CEO Ivan Tornos, who assumed the role in late 2023 after serving as the company’s COO and holding executive positions at Becton Dickinson and Baxter International. The leadership team includes EVP and CFO Suketu Upadhyay, who brings extensive financial expertise from Bristol-Myers Squibb, and Dr. Nitin Goyal, a practicing orthopedic surgeon serving as Chief Science, Technology, and Innovation Officer to align R&D with clinical demands. The Board of Directors is chaired by Christopher Begley, former CEO of Hospira, and includes notable members such as Maria Teresa Hilado, former CFO of Allergan. As a prominent S&P 500 constituent, ZBH maintains a robust institutional investor base led by The Vanguard Group, BlackRock, and State Street Corporation, reflecting its status as a cornerstone of the global medical technology infrastructure.